This study evaluates the impact of reducing sitting time and increasing exercise time on cardiometabolic health in persons with Multiple Sclerosis.
To date, it is clear that sedentary behaviour is strongly related to an increased risk of type II diabetes, cardiovascular disease and premature mortality. People suffering from chronic disabilities appear to be particularly susceptible to a sedentary lifestyle and inactivity due to primary disease symptoms. To date, this is an important new research topic in Multiple Sclerosis (MS, \~2.3 million people worldwide, \~10-12.000 diagnosed in Belgium) treatment, since previous research reported a significantly higher prevalence of sedentary behaviour in persons with MS (PwMS) compared to healthy controls (HC). PwMS are reported to have a 40% lower daily step count compared to healthy inactive persons and tend to accumulate their sedentary time in longer bouts. As described above and similar to other chronic conditions, a sedentary lifestyle also makes PwMS more vulnerable to the accumulation of important cardiometabolic comorbidities that seem inactivity-related rather than a direct result of non-reversible tissue injury. Such comorbidities include impaired whole body glycaemic control, an abnormal blood lipid profile, an unhealthy body composition and hypertension. In this respect, it is important to note that corticosteroids, which are often used to treat MS patients pharmacologically, elevate fasting glucose and insulin concentrations and induce insulin resistance in HC therefore probably also increase several cardiometabolic risk factors in MS. Up to now, research in MS has been focused on structured exercise and its positive effects on functional parameters are well-known (e.g. improvements in cardiorespiratory fitness, muscle strength, balance, fatigue, cognition, quality of life and respiratory function). However, evidence is growing that sedentary time, independent of the (dis)practice of structured exercise, is an important independent health risk factor. Consequently, any strategy that also improves cardiometabolic health may help to further optimize rehabilitation in MS. Breaking up and reducing sedentary time with easy, daily activities such as household activities and other activities which increase light-intensity walking and standing, known as non-exercise physical activity (NEPA) may be such a strategy. NEPA has already been shown to significantly improve cardiometabolic risk markers in healthy, sedentary subjects, type II diabetes patients and obese adults and it involves lower intensity physical activities that are probably more feasible for PwMS. Moreover, with comparable activity workloads, reducing sitting time by NEPA of longer duration decreases insulin levels and fasting lipid levels more than performing one structured exercise bout of moderate intensity that is usually described in current activity guidelines. So far however, acute exercise bouts and NEPA effects on cardiometabolic health in this population have never been described. Therefore, the aim of this study is to investigate whether (1) cardiometabolic health (glycaemic control, blood lipids, inflammation markers and blood pressure) of persons with MS improves when sedentary time is reduced and (2) NEPA results in better cardiometabolic health parameters than (a shorter daily bout of) moderate-intensity exercise when workload of both activities is identical in this population.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
28
This is a baseline measurement of physical activity during which subjects will be instructed not to change activity patterns during four days and to note all activities they perform.
Participants have to spend 14h of their day sitting, 1h walking and 1h standing, for four consecutive days. According to the compendium of Ainsworth et al. (2011), this corresponds with a daily workload of activities (DWA) of 27 metabolic equivalents (MET's) per day.
Each day (4 days in total) will consist of 3h walking, 4h standing and 9h sitting. These time frames are chosen to result in a comparable DWA increase as the exercise regime compared to the sit regime (+7 MET's)27. The additional 2h of walking and 3h of standing, compared to the sitting regime, will be done in a minimum of four bouts with a time interval of \> 1h. The subjects will be instructed to walk on a slow pace. i.e. 2-3 km/h (e.g. walking during shopping and work related walking in an office).
Hasselt University
Diepenbeek, Limburg, Belgium
Steps per day
Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK).
Time frame: Day 1 to 4 of the control regime
Sitting time
Sedentary behaviour will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK).
Time frame: Day 1 to 4 of the control regime
Standing time
Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK).
Time frame: Day 1 to 4 of the control regime
Stepping time
Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK).
Time frame: Day 1 to 4 of the control regime
Concentration of glucose
Blood analysis
Time frame: Day after the control regime
Concentration of insulin
Blood analysis
Time frame: Day after the control regime
Concentration of total cholesterol
Blood analysis
Time frame: Day after the control regime
Concentration of high density lipoprotein cholesterol (HDL-cholesterol)
Blood analysis
Time frame: Day after the control regime
Concentration of low density lipoprotein cholesterol (LDL-cholesterol)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
One hour of sitting in the sit regime will be replaced with 1 training session (1h) on a cycle ergometer in the research center. The remaining hours of each day (4 days in total) have to be spent as follows: 13h sitting, 1h walking and 1h standing for daily care. The intensity of the training session (50-60% of Wmax) results in a DWA of 34.5 MET's according to the compendium of physical activities. Duration of training sessions will be adapted individually with ActivPAL data of the sit less and sit regime to identically match DWA increase between the sit less and exercise regime, compared to the sitting regime.
Blood analysis
Time frame: Day after the control regime
Concentration of non-high densitiy lipoprotein cholesterol (non-HDL cholesterol)
Blood analysis
Time frame: Day after the control regime
Concentration of triglyceride
Blood analysis
Time frame: Day after the control regime
Concentration of apolipoprotein A1 (apo A1)
Blood analysis
Time frame: Day after the control regime
Concentration of apolipoprotein B (apo B)
Blood analysis
Time frame: Day after the control regime
Concentration of free fatty acids (FFA)
Blood analysis
Time frame: Day after the control regime
Concentration of C-reactive protein (CRP)
Blood analysis
Time frame: Day after the control regime
Concentration of interleukin 1 (IL-1)
Blood analysis
Time frame: Day after the control regime
Concentration of interleukin 6 (IL-6)
Blood analysis
Time frame: Day after the control regime
Steps per day
Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK).
Time frame: Day 1 to 4 of the Sit regime
Sitting time
Sedentary behaviour will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK).
Time frame: Dag 1 to 4 of the Sit regime
Standing time
Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK).
Time frame: Day 1 to 4 of the Sit regime
Stepping time
Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK).
Time frame: Day 1 to 4 of the Sit regime
Concentration of glucose
Blood analysis
Time frame: Day after the Sit regime
Concentration of insulin
Blood analysis
Time frame: Day after the Sit regime
Concentration of total cholesterol
Blood analysis
Time frame: Day after the Sit regime
Concentration of high density lipoprotein cholesterol (HDL-cholesterol)
Blood analysis
Time frame: Day after the Sit regime
Concentration of low density lipoprotein cholesterol (LDL-cholesterol)
Blood analysis
Time frame: Day after the Sit regime
Concentration of non-high densitiy lipoprotein cholesterol (non-HDL cholesterol)
Blood analysis
Time frame: Day after the Sit regime
Concentration of triglyceride
Blood analysis
Time frame: Day after the Sit regime
Concentration of apolipoprotein A1 (apo A1)
Blood analysis
Time frame: Day after the Sit regime
Concentration of apolipoprotein B (apo B)
Blood analysis
Time frame: Day after the Sit regime
Concentration of free fatty acids (FFA)
Blood analysis
Time frame: Day after the Sit regime
Concentration of C-reactive protein (CRP)
Blood analysis
Time frame: Day after the Sit regime
Concentration of interleukin 1 (IL-1)
Blood analysis
Time frame: Day after the Sit regime
Concentration of interleukin 6 (IL-6)
Blood analysis
Time frame: Day after the Sit regime
Steps per day
Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK).
Time frame: Day 1 to 4 of the Sit Less regime
Sitting time
Sedentary behaviour will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK).
Time frame: Day 1 to 4 of the Sit Less regime
Standing time
Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK).
Time frame: Day 1 to 4 of the Sit Less regime
Stepping time
Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK).
Time frame: Day 1 to 4 of the Sit Less regime
Concentration of glucose
Blood analysis
Time frame: Day after the Sit Less regime
Concentration of insulin
Blood analysis
Time frame: Day after the Sit Less regime
Concentration of total cholesterol
Blood analysis
Time frame: Day after the Sit Less regime
Concentration of high density lipoprotein cholesterol (HDL-cholesterol)
Blood analysis
Time frame: Day after the Sit Less regime
Concentration of low density lipoprotein cholesterol (LDL-cholesterol)
Blood analysis
Time frame: Day after the Sit Less regime
Concentration of non-high densitiy lipoprotein cholesterol (non-HDL cholesterol)
Blood analysis
Time frame: Day after the Sit Less regime
Concentration of triglyceride
Blood analysis
Time frame: Day after the Sit Less regime
Concentration of apolipoprotein A1 (apo A1)
Blood analysis
Time frame: Day after the Sit Less regime
Concentration of apolipoprotein B (apo B)
Blood analysis
Time frame: Day after the Sit Less regime
Concentration of free fatty acids (FFA)
Blood analysis
Time frame: Day after the Sit Less regime
Concentration of C-reactive protein (CRP)
Blood analysis
Time frame: Day after the Sit Less regime
Concentration of interleukin 1 (IL-1)
Blood analysis
Time frame: Day after the Sit Less regime
Concentration of interleukin 6 (IL-6)
Blood analysis
Time frame: Day after the Sit Less regime
Steps per day
Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK).
Time frame: Day 1 to 4 of the Exercise regime
Sitting time
Sedentary behaviour will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK).
Time frame: Day 1 to 4 of the Exercise regime
Standing time
Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK).
Time frame: Day 1 to 4 of the Exercise regime
Stepping time
Physical activity will be measured with the ActivPAL3TM activity monitor (PAL Technologies Ltd, Glasgow, UK).
Time frame: Day 1 to 4 of the Exercise regime
Concentration of glucose
Blood analysis
Time frame: Day after the Exercise regime
Concentration of insulin
Blood analysis
Time frame: Day after the Exercise regime
Concentration of total cholesterol
Blood analysis
Time frame: Day after the Exercise regime
Concentration of high density lipoprotein cholesterol (HDL-cholesterol)
Blood analysis
Time frame: Day after the Exercise regime
Concentration of low density lipoprotein cholesterol (LDL-cholesterol)
Blood analysis
Time frame: Day after the Exercise regime
Concentration of non-high densitiy lipoprotein cholesterol (non-HDL cholesterol)
Blood analysis
Time frame: Day after the Exercise regime
Concentration of triglyceride
Blood analysis
Time frame: Day after the Exercise regime
Concentration of apolipoprotein A1 (apo A1)
Blood analysis
Time frame: Day after the Exercise regime
Concentration of apolipoprotein B (apo B)
Blood analysis
Time frame: Day after the Exercise regime
Concentration of free fatty acids (FFA)
Blood analysis
Time frame: Day after the Exercise regime
Concentration of C-reactive protein (CRP)
Blood analysis
Time frame: Day after the Exercise regime
Concentration of interleukin 1 (IL-1)
Blood analysis
Time frame: Day after the Exercise regime
Concentration of interleukin 6 (IL-6)
Blood analysis
Time frame: Day after the Exercise regime
Blood pressure
Systolic, diastolic and mean arterial blood pressure will be measured 3 times at 5-min intervals using an electronic sphygmomanometer (Omron®, Omron Healthcare, IL, USA) from the dominant arm and documented as the mean value of the final 2 measurements.
Time frame: Day after the Control regime
Body weight
Body weight (in underwear) is determined using a digital-balanced weighting scale to the nearest 0.1kg
Time frame: Day after the Control regime
Blood pressure
Systolic, diastolic and mean arterial blood pressure will be measured 3 times at 5-min intervals using an electronic sphygmomanometer (Omron®, Omron Healthcare, IL, USA) from the dominant arm and documented as the mean value of the final 2 measurements.
Time frame: Day after the Sit regime
Body weight
Body weight (in underwear) is determined using a digital-balanced weighting scale to the nearest 0.1kg
Time frame: Day after the Sit regime
Blood pressure
Systolic, diastolic and mean arterial blood pressure will be measured 3 times at 5-min intervals using an electronic sphygmomanometer (Omron®, Omron Healthcare, IL, USA) from the dominant arm and documented as the mean value of the final 2 measurements.
Time frame: Day after the Sit Less regime
Body weight
Body weight (in underwear) is determined using a digital-balanced weighting scale to the nearest 0.1kg
Time frame: Day after the Sit Less regime
Blood pressure
Systolic, diastolic and mean arterial blood pressure will be measured 3 times at 5-min intervals using an electronic sphygmomanometer (Omron®, Omron Healthcare, IL, USA) from the dominant arm and documented as the mean value of the final 2 measurements.
Time frame: Day after the Exercise regime
Body weight
Body weight (in underwear) is determined using a digital-balanced weighting scale to the nearest 0.1kg
Time frame: Day after the Exercise regime